Miromatrix Medical Inc. (MIRO)
Miromatrix Medical Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Eden Prairie, MN, US. The stock last traded at $3.39, up 0.59% on the session, giving a market capitalisation of $93.0M. On trailing twelve-month figures it carries a trailing P/E of -2.34, a net margin of -3147.2%. Its beta of 0.01 implies it has historically moved less than the broad market.
Miromatrix Medical Inc. is a life sciences company dedicated to pioneering a novel technology for bioengineering organs that are fully transplantable. Central to its innovative work is a proprietary platform utilizing a two-stage method involving decellularization and recellularization. This sophisticated process entails meticulously removing the native porcine cells from organs harvested from pigs, then introducing unmodified human cells to create viable new structures. Miromatrix maintains significant partnerships with esteemed medical institutions such as The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company, which was originally incorporated in 2009 under the name TayTech, Inc., operates from its headquarters in Eden Prairie, Minnesota.
Miromatrix Medical Inc. is most often compared with the following Healthcare names: